The price-to-earnings ratio for Royalty Pharma plc (NASDAQ: RPRX) is 11.53x, which is above its average ratio. Moreover, the 36-month beta value for RPRX is 0.45. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for RPRX is 378.53M and currently, short sellers hold a 3.34% of that float. On April 09, 2024, RPRX’s average trading volume was 2.67M shares.
RPRX) stock’s latest price update
The stock price of Royalty Pharma plc (NASDAQ: RPRX) has surged by 0.17 when compared to previous closing price of 29.19, but the company has seen a -2.21% decline in its stock price over the last five trading sessions. InvestorPlace reported 2024-03-27 that With the market trading near all-time highs, undervalued healthcare stocks offer a compelling opportunity. Fundamentally, the sector could benefit from a rotation in the innovation ecosystem.
RPRX’s Market Performance
Royalty Pharma plc (RPRX) has experienced a -2.21% fall in stock performance for the past week, with a -2.66% drop in the past month, and a 6.48% rise in the past quarter. The volatility ratio for the week is 2.27%, and the volatility levels for the past 30 days are at 1.80% for RPRX. The simple moving average for the past 20 days is -2.43% for RPRX’s stock, with a 0.99% simple moving average for the past 200 days.
Analysts’ Opinion of RPRX
Many brokerage firms have already submitted their reports for RPRX stocks, with UBS repeating the rating for RPRX by listing it as a “Buy.” The predicted price for RPRX in the upcoming period, according to UBS is $47 based on the research report published on June 14, 2022 of the previous year 2022.
Scotiabank, on the other hand, stated in their research note that they expect to see RPRX reach a price target of $53. The rating they have provided for RPRX stocks is “Sector Outperform” according to the report published on May 13th, 2022.
Goldman gave a rating of “Buy” to RPRX, setting the target price at $56 in the report published on April 27th of the previous year.
RPRX Trading at -1.84% from the 50-Day Moving Average
After a stumble in the market that brought RPRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -20.40% of loss for the given period.
Volatility was left at 1.80%, however, over the last 30 days, the volatility rate increased by 2.27%, as shares sank -3.72% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +0.45% upper at present.
During the last 5 trading sessions, RPRX fell by -2.21%, which changed the moving average for the period of 200-days by -5.62% in comparison to the 20-day moving average, which settled at $29.91. In addition, Royalty Pharma plc saw 4.09% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RPRX starting from RIGGS RORY B, who sale 35,702 shares at the price of $27.55 back on Jan 04 ’24. After this action, RIGGS RORY B now owns 20,099 shares of Royalty Pharma plc, valued at $983,504 using the latest closing price.
RIGGS RORY B, the Director of Royalty Pharma plc, sale 199,098 shares at $27.79 during a trade that took place back on Jan 03 ’24, which means that RIGGS RORY B is holding 55,801 shares at $5,532,276 based on the most recent closing price.
Stock Fundamentals for RPRX
Current profitability levels for the company are sitting at:
- 0.63 for the present operating margin
- 0.73 for the gross margin
The net margin for Royalty Pharma plc stands at 0.48. The total capital return value is set at 0.09. Equity return is now at value 18.68, with 6.84 for asset returns.
Based on Royalty Pharma plc (RPRX), the company’s capital structure generated 0.48 points at debt to capital in total, while cash flow to debt ratio is standing at 0.49. The debt to equity ratio resting at 0.94. The interest coverage ratio of the stock is 7.98.
Currently, EBITDA for the company is 1.49 billion with net debt to EBITDA at 3.57. When we switch over and look at the enterprise to sales, we see a ratio of 7.95. The receivables turnover for the company is 3.04for trailing twelve months and the total asset turnover is 0.14. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.90.
Conclusion
To wrap up, the performance of Royalty Pharma plc (RPRX) has been mixed in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
